AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
IND Edition 
⚠
✓
Acrivon Therapeutics, Inc. Common Stock (NASDAQ:ACRV)
1.57 USD
+0.050 3.290%Sponsored Reports
Loading...
| Previous Close (in USD) | 1.52 |
|---|---|
| Change | +0.050 3.290% |
| 52 W H/L (in USD) | 3.560/1.050 |
| EBITDA (in USD) | -82.758M |
| PE Ratio | -- |
| Volume | 713718 |
| Diluted Eps TTM | -2.02 |
| Total Assets (in USD) | 129.717M |
|---|---|
| Total Liabilities (in USD) | 17.201M |
| Revenue TTM (in USD) | -- |
| Cash (in USD) | 41.499M |
| Market Cap (in USD) | 68.190 M |
| Revenue Per Share TTM | -- |
| Gross Profit TTM (in USD) | -- |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Acrivon Therapeutics, Inc. Common Stock
Acrivon Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2 for the treatment of patients with endometrial and platinum-resistant ovarian cancer, and SCCs, such as SCCHN and anal cancer. The company is also developing ACR-2316, a dual WEE1 and PKMYT1 inhibitor small molecule candidate; and a preclinical stage AP3-and co-crystallography-based preclinical cell cycle program. The company was incorporated in 2018 and is based in Watertown, Massachusetts.
Employees: 74
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Dr. Peter Blume-Jensen M.D., Ph.D. | Co-Founder, Chairman, CEO, Pres & Acting Chief Scientific Officer | 1962 |
| 2. | Ms. Kristina Masson Ph.D. | Co-Founder, Exec. VP of Bus. Operations, Treasurer, Sec. & Director | 1980 |
| 3. | Dr. Eric J. Devroe Ph.D. | Chief Operating Officer | 1978 |
| 4. | Mr. Erick Gamelin M.D., Ph.D. | Chief Medical Officer | 1957 |
| 5. | Mr. Rasmus Holm-Jorgensen | Chief Financial Officer | 1971 |
| 6. | Ms. Katharine Peterson CPA | VP of Fin. & Accounting | NA |
| 7. | Mr. Bruce Close | VP of Quality & Compliance | NA |
| 8. | Ms. Mary-Alice Miller J.D. | Gen. Counsel | 1974 |
| 9. | Ms. Crystal Mercado | Global Head of HR | NA |
| 10. | Dr. Jesper V. Olsen Ph.D. | Academic Co-Founder, Head of Phosphoproteomics & Member of Scientific Advisory Board | NA |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
-0.330 0.758% | 43.45 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
0.000 0.000% | 43 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
-7.360 1.604% | 462.17 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
+2.010 0.331% | 612.07 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2025 | 31-12-2024 | 31-12-2023 | 31-12-2022 | 31-12-2021 |
|---|---|---|---|---|---|
| Income Before Tax | -77.905M | -80.556M | -60.388M | -31.167M | -16.243M |
| Minority Interest | - | - | - | - | - |
| Net Income | -77.905M | -80.556M | -60.388M | -29.677M | -16.243M |
| Selling General Administrative | 24.124M | 25.207M | 21.079M | 8.708M | 2.466M |
| Gross Profit | -1.356M | -1.006M | -0.536M | - | - |
| Reconciled Depreciation | 1.356M | 1.006M | 0.512M | 0.364M | 0.037M |
| Ebit | -84.114M | -80.556M | -60.388M | -33.021M | -16.184M |
| Ebitda | -82.758M | -79.55M | -59.852M | -32.657M | -16.147M |
| Depreciation And Amortization | 1.356M | 1.006M | 0.536M | 0.364M | 0.037M |
| Operating Income | -84.114M | -89.199M | -67.237M | -32.657M | -16.184M |
| Other Operating Expenses | 84.114M | 89.199M | 67.237M | 32.657M | 16.184M |
| Interest Expense | - | - | - | -1.49M | 0.059M |
| Tax Provision | - | - | - | - | - |
| Interest Income | 6.479M | 9.201M | 7.037M | - | - |
| Net Interest Income | 6.479M | 9.201M | 7.037M | - | - |
| Income Tax Expense | - | - | 0M | -1.49M | 0.059M |
| Total Revenue | 0M | 0M | 0M | 0M | 0M |
| Total Operating Expenses | 82.758M | 88.193M | 66.701M | 32.657M | 16.184M |
| Cost Of Revenue | 1.356M | 1.006M | 0.536M | - | - |
| Total Other Income Expense Net | 6.209M | 8.643M | 6.849M | 1.49M | -0.059M |
| Net Income From Continuing Ops | -77.905M | -80.556M | -50.065M | -31.167M | -16.243M |
| Net Income Applicable To Common Shares | - | - | - | -31.167M | -16.243M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2025 | 31-12-2024 | 31-12-2023 | 31-12-2022 | 31-12-2021 |
|---|---|---|---|---|---|
| Total Assets | 129.717M | 196.588M | 138.265M | 181.226M | 106.587M |
| Intangible Assets | - | - | - | - | - |
| Other Current Assets | 1.863M | 2.149M | 2.234M | 4.344M | 0.805M |
| Total Liab | 17.201M | 19.802M | 17.07M | 10.751M | 130.396M |
| Total Stockholder Equity | 112.516M | 176.786M | 121.195M | 170.475M | -23.809M |
| Other Current Liab | 12.215M | 15.399M | 7.378M | 4.817M | 1.22M |
| Common Stock | 0.031M | 0.031M | 0.023M | 0.022M | 0.002M |
| Capital Stock | 0.031M | 0.031M | 0.023M | 0.022M | 0.002M |
| Retained Earnings | -274.881M | -196.976M | -116.42M | -56.032M | -24.865M |
| Good Will | - | - | - | - | - |
| Other Assets | - | - | 0M | 0.388M | 0.388M |
| Cash | 41.499M | 39.818M | 36.015M | 29.519M | 99.603M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 15.664M | 17.214M | 13.303M | 6.516M | 2.914M |
| Current Deferred Revenue | - | - | - | 0.069M | 0.066M |
| Net Debt | -38.79M | -36.173M | -31.371M | -24.558M | -93.975M |
| Short Term Debt | 1.172M | 1.057M | 0.877M | 0.726M | 0.664M |
| Short Long Term Debt | - | - | - | - | - |
| Short Long Term Debt Total | 2.709M | 3.645M | 4.644M | 4.961M | 5.628M |
| Other Stockholder Equity | 387.255M | 373.284M | 237.675M | 45.354M | 1.054M |
| Property Plant Equipment | - | - | - | 2.092M | 5.791M |
| Total Current Assets | 120.445M | 181.629M | 129.692M | 127.751M | 100.408M |
| Long Term Investments | 0M | 5.089M | 0M | 41.881M | - |
| Short Term Investments | 77.083M | 139.662M | 91.443M | 98.232M | - |
| Net Receivables | - | - | - | - | - |
| Long Term Debt | - | - | - | - | - |
| Inventory | - | - | - | - | - |
| Accounts Payable | 2.277M | 0.758M | 5.048M | 0.904M | 0.964M |
| Accumulated Other Comprehensive Income | 0.111M | 0.447M | -0.083M | -0.095M | - |
| Non Currrent Assets Other | 1.856M | 1.845M | 0.251M | 4.732M | 0.388M |
| Non Current Assets Total | 9.272M | 14.959M | 8.573M | 53.475M | 6.179M |
| Capital Lease Obligations | 2.709M | 3.645M | 4.644M | 4.961M | 5.628M |
| Long Term Debt Total | - | - | - | - | - |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2025 | 31-12-2024 | 31-12-2023 | 31-12-2022 | 31-12-2021 |
|---|---|---|---|---|---|
| Investments | 67.769M | -51.771M | -64.886M | -139.51M | -0.238M |
| Total Cashflows From Investing Activities | 66.1M | -51.771M | 50.717M | -141.676M | -0.238M |
| Total Cash From Financing Activities | -0.749M | 121.027M | -1.554M | 101.709M | 112.221M |
| Net Income | -77.905M | -80.556M | -60.388M | -31.167M | -16.243M |
| Change In Cash | 1.686M | 3.587M | 6.522M | -70.084M | 98.001M |
| Begin Period Cash Flow | 40.016M | 36.429M | 29.907M | 99.991M | 1.99M |
| End Period Cash Flow | 41.702M | 40.016M | 36.429M | 29.907M | 99.991M |
| Total Cash From Operating Activities | -63.665M | -65.669M | -42.641M | -30.117M | -13.982M |
| Depreciation | 0.919M | 1.006M | 0.536M | 0.364M | 0.037M |
| Other Cashflows From Investing Activities | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Change To Inventory | - | - | - | - | - |
| Sale Purchase Of Stock | - | - | - | 101.709M | - |
| Other Cashflows From Financing Activities | -0.75M | 51.03M | -1.297M | -2.749M | -0.238M |
| Capital Expenditures | 1.669M | 2.768M | 1.288M | 2.166M | 0.238M |
| Change In Working Capital | -2.426M | 2.438M | 8.138M | -1.532M | 0.328M |
| Other Non Cash Items | 1.027M | -2.845M | 1.064M | 0.033M | 1.144M |
| Free Cash Flow | -65.334M | -68.437M | -43.929M | -32.283M | -14.22M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Bridgeway Ultra-Small Company Market | 5 months ago | 38000 |
| 2. | Vanguard Total Stock Mkt Idx Inv | 2 months ago | 545541 |
| 3. | Lago Erie SICAV | 3 months ago | 194437 |
| 4. | Vanguard Institutional Extnd Mkt Idx Tr | 2 months ago | 176494 |
| 5. | A4Investments SICAV SIF ACCI IlanaA2EURH | 2 months ago | 130000 |
| 6. | Fidelity Extended Market Index | 3 months ago | 110324 |
| 7. | Vifag 2002 SICAV | 3 months ago | 67500 |
| 8. | Extended Equity Market Fund B | 5 months ago | 49407 |
| 9. | Blackrock Extended Mkt Fund CF | 3 months ago | 49407 |
| 10. | Extended Equity Market Fund E | 5 months ago | 49407 |
| 11. | iShares Micro-Cap ETF | 2 months ago | 44872 |
| 12. | Extended Equity Market Fund K | 2 months ago | 42069 |
| 13. | Nationwide Bailard Sm Cp Val M | 4 months ago | 29799 |
| 14. | Fidelity Series Total Market Index | 3 months ago | 24820 |
| 15. | Fidelity Total Market Index | 3 months ago | 24809 |
| 16. | NT Ext Equity Mkt Idx Fd - L | 2 months ago | 22267 |
| 17. | Vanguard Instl Ttl Stck Mkt Idx Tr | 2 months ago | 19421 |
| 18. | Spartan Extended Market Index Pool F | 3 months ago | 18616 |
| 19. | Fidelity Nasdaq Composite Index | 3 months ago | 18053 |
| 20. | Northern Trust Extended Eq Market Idx | 8 months ago | 15531 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Bridgeway Capital Management, LLC | 5 months ago | 42900 |
| 2. | RA Capital Management, LLC | 5 months ago | 8340508 |
| 3. | Sands Capital Ventures, LLC | 5 months ago | 2122605 |
| 4. | Citadel Advisors Llc | 5 months ago | 1641884 |
| 5. | Wellington Management Company LLP | 5 months ago | 888130 |
| 6. | Vanguard Group Inc | 5 months ago | 698857 |
| 7. | UBS Group AG | 8 months ago | 683218 |
| 8. | Renaissance Technologies Corp | 5 months ago | 634169 |
| 9. | Two Sigma Investments LLC | 5 months ago | 585069 |
| 10. | Marshall Wace Asset Management Ltd | 5 months ago | 496081 |
| 11. | Jane Street Group LLC | 5 months ago | 342071 |
| 12. | Two Sigma Advisers, LLC | 5 months ago | 333773 |
| 13. | BlackRock Inc | 8 months ago | 330957 |
| 14. | Geode Capital Management, LLC | 5 months ago | 198223 |
| 15. | Millennium Management LLC | 5 months ago | 121524 |
| 16. | The Goldman Sachs Group Inc | 5 months ago | 119422 |
| 17. | State Street Corp | 8 months ago | 67145 |
| 18. | Morgan Stanley - Brokerage Accounts | 8 months ago | 57160 |
| 19. | Springbok Capital Management, LLC | 5 months ago | 48015 |
| 20. | Northern Trust Corp | 8 months ago | 42166 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...